Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression ... The Institute for Clinical and Economic Review (ICER) has published its final report on Spravato ...
The decision came after a priority review ... Johnson's nasal spray as a standalone treatment for severe forms of depression, officials said. The FDA granted approval to Spravato (esketamine ...
The FDA approval comes after a priority review and is based on the ... which showed that Spravato administered as a nasal spray achieved a rapid and statistically significant improvement in ...
The remaining 20% is their coinsurance. S-ketamine, or esketamine (Spravato), is an FDA-approved nasal spray that doctors and healthcare professionals may prescribe for major depressive disorder ...